Foundation invests millions to find MS drug leads

The Myelin Repair Foundation has spent $10 million so far to identify 18 new drug leads for multiple sclerosis. The non-profit foundation says it plans to roll out the two best leads to pharma companies this summer, hoping for a licensing deal that will swiftly advance a new drug for MS.

The Foundation is helping blaze a path in new drug research, taking millions of dollars in donations and advancing experimental new therapies to the point that a drug company would want to in-license them for commercial development. And the Foundation is prepared to take a smaller payback in exchange for a faster development path.

- check out the report in the San Francisco Chronicle

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.